{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.5","value":"69.8"},{"groupId":"OG001","spread":"28.2","value":"55.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"description":"AUC(0-Infinity) is the area under the plasma concentration versus time curve from time 0 to the infinite time of midazolam alone or in combination with erdafitinib.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received single dose of pretreatment midazolam 2.5 mg syrup, orally, once daily, starting from Day -2 through Day 13 of Cycle 1 (each cycle length=28 days).","id":"OG000","title":"DDI Study: Midazolam 2.5 mg Alone"},{"description":"Participants received single dose of pretreatment midazolam 2.5 mg syrup, orally, once daily, starting from Day -2 through Day 13 of Cycle 1 along with erdafitinib 8 mg starting from Day 1 up to Day 15 of Cycle 1 (each cycle length=28 days).","id":"OG001","title":"DDI Study: Midazolam 2.5 mg + Erdafitinib 8 mg"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic analysis set included all participants who received at least 1 dose of study drug and had at least 1 sample collected during treatment to determine the drug concentration. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)","title":"Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Infinite Time (AUC[0-Infinity]) of Midazolam Alone or in Combination With Erdafitinib","type":"PRIMARY","unitOfMeasure":"ng*h/mL"}